[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100477066":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":42,"centralContacts":46,"locations":53,"responsibleParty":282,"collaborators":284,"id":290,"slug":291,"hasResults":292,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":51,"eligibilityCriteria":296,"healthyVolunteers":292,"sex":297,"minAge":298,"maxAge":299,"enrollmentInfo":300,"targetDuration":51,"studyType":303,"phases":304,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":56,"whyStopped":51,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":324},{"fullName":5,"class":6},"Hospital Israelita Albert Einstein","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Chemoradiation","ACTIVE_COMPARATOR","Traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly cisplatin 40mg\u002Fm2\u002Fweek or carboplatin AUC 2\u002Fweek",[13],"Radiation: Chemoradiation",{"label":15,"type":16,"description":17,"interventionNames":18},"Immunotherapy","EXPERIMENTAL","4 cycles of induction therapy with nivolumab 1mg\u002Fkg and ipilimumab 3mg\u002Fkg every 3 weeks followed by traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly cisplatin 40mg\u002Fm2\u002Fweek (or carboplatin AUC 2\u002Fweek) with concurrent nivolumab 240mg every 2 weeks.",[19,20,13],"Drug: Nivolumab 40 mg in 4 ml Injection","Drug: Ipilimumab 200 MG in 40 ML Injection",[22,29,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Nivolumab 40 mg in 4 ml Injection","Nivolumab 1mg\u002Fkg every 3 weeks for 4 cycles prior to radiation and 240mg every 2 weeks with concurrent radiation",[15],[28],"Opdivo",{"type":23,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Ipilimumab 200 MG in 40 ML Injection","Ipilimumab 3mg\u002Fkg every 3 weeks for 4 cycles prior to radiation",[15],[34],"Yervoy",{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"RADIATION","Chemoradiation","Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg\u002Fm2\u002Fw or carboplatin AUC 2\u002Fw",[15,9],[41],"Cisplatin-based chemoradiation",[43],{"name":44,"affiliation":5,"role":45},"Fernando Maluf, MD","PRINCIPAL_INVESTIGATOR",[47],{"name":48,"role":49,"phone":50,"phoneExt":51,"email":52},"Diogo Bugano, MD","CONTACT","+55-11-2151-0240",null,"diogo.gomes@einstein.br",[54,75,91,109,126,143,159,176,193,210,226,242,257,271],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"CRIO -Centro Regional Integrado de Oncologia","RECRUITING","Fortaleza","Ceará","60335-480","Brazil","BR",{"type":63,"coordinates":64},"Point",[65,66],-38.54306,-3.71722,{"lat":66,"lon":65},[69,73],{"name":70,"role":49,"phone":71,"phoneExt":51,"email":72},"Eduardo Cronemberger","+55(85)3286-5934","cronmeberger.eduardo@gmail.com",{"name":74,"role":45,"phone":51,"phoneExt":51,"email":51},"Eduardo Cronemberger, MD",{"facility":76,"status":56,"city":77,"state":78,"zip":79,"country":60,"countryCode":61,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Clinica AMO","Salvador","Estado de Bahia","41810-011",{"type":63,"coordinates":81},[82,83],-38.49096,-12.97563,{"lat":83,"lon":82},[86,90],{"name":87,"role":49,"phone":88,"phoneExt":51,"email":89},"Aknar Calabrich","+55(71)3021-8735","aknar@clinicaamo.com.br",{"name":87,"role":45,"phone":51,"phoneExt":51,"email":51},{"facility":92,"status":93,"city":94,"state":95,"zip":96,"country":60,"countryCode":61,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Hospital das Clinicas da UFMG","NOT_YET_RECRUITING","Belo Horizonte","Minas Gerais","30130-100",{"type":63,"coordinates":98},[99,100],-43.93778,-19.92083,{"lat":100,"lon":99},[103,107],{"name":104,"role":49,"phone":105,"phoneExt":51,"email":106},"Angélica Nogueira","+55(31)3307-9255","angélica.onco@uol.com.br",{"name":108,"role":45,"phone":51,"phoneExt":51,"email":51},"Angélica Nogueira, MD",{"facility":110,"status":93,"city":111,"state":112,"zip":113,"country":60,"countryCode":61,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Hospital Erasto Gaertner","Curitiba","Paraná","81520-060",{"type":63,"coordinates":115},[116,117],-49.27306,-25.42778,{"lat":117,"lon":116},[120,124],{"name":121,"role":49,"phone":122,"phoneExt":51,"email":123},"Reitan Ribeiro","+55(41)3361-5195","reitanribeiro@hotmail.com",{"name":125,"role":45,"phone":51,"phoneExt":51,"email":51},"Reitan Ribeiro, MD",{"facility":127,"status":56,"city":128,"state":129,"zip":130,"country":60,"countryCode":61,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Multi Oncoclinicas Recife","Recife","Pernambuco","50070-460",{"type":63,"coordinates":132},[133,134],-34.88111,-8.05389,{"lat":134,"lon":133},[137,141],{"name":138,"role":49,"phone":139,"phoneExt":51,"email":140},"Carla Rameri","+55(81)2122-4792","carla.rameri.de.azevedo@gmail.com",{"name":142,"role":45,"phone":51,"phoneExt":51,"email":51},"Carla Rameri, MD",{"facility":144,"status":93,"city":145,"state":146,"zip":147,"country":60,"countryCode":61,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Hospital São Lucas - PUCRS","Porto Alegre","Rio Grande do Sul","90610-001",{"type":63,"coordinates":149},[150,151],-51.23019,-30.03283,{"lat":151,"lon":150},[154,158],{"name":155,"role":49,"phone":156,"phoneExt":51,"email":157},"Fernanda Damian","+55(51)3320-3039","fernandadamian@yahoo.com.br",{"name":155,"role":45,"phone":51,"phoneExt":51,"email":51},{"facility":160,"status":56,"city":161,"state":162,"zip":163,"country":60,"countryCode":61,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"Universidade Federal de Roraima","Boa Vista","Roraima","69310-000",{"type":63,"coordinates":165},[166,167],-60.67333,2.81972,{"lat":167,"lon":166},[170,174],{"name":171,"role":49,"phone":172,"phoneExt":51,"email":173},"Allex Jardim","+55(95)3224-4712","allex.j.fonseca@gmail.com",{"name":175,"role":45,"phone":51,"phoneExt":51,"email":51},"Allex Jardim, MD, PhD",{"facility":177,"status":93,"city":178,"state":179,"zip":180,"country":60,"countryCode":61,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"CEPON - Florianópolis","Florianópolis","Santa Catarina","88034-000",{"type":63,"coordinates":182},[183,184],-48.54917,-27.59667,{"lat":184,"lon":183},[187,191],{"name":188,"role":49,"phone":189,"phoneExt":51,"email":190},"Anne Schmitz","+55(48)3331-1553","anneschmitz@uol.com.br",{"name":192,"role":45,"phone":51,"phoneExt":51,"email":51},"Anne Schmitz, MD",{"facility":194,"status":93,"city":195,"state":196,"zip":197,"country":60,"countryCode":61,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"Hospital de Amor","Barretos","São Paulo","14784-400",{"type":63,"coordinates":199},[200,201],-48.56778,-20.55722,{"lat":201,"lon":200},[204,208],{"name":205,"role":49,"phone":206,"phoneExt":51,"email":207},"Maria Fernanda Biazzotto","+55(17)3321-6638","nandabiazotto@hotmail.com",{"name":209,"role":45,"phone":51,"phoneExt":51,"email":51},"Maria Fernanca Biazzotto, MD",{"facility":211,"status":93,"city":212,"state":196,"zip":213,"country":60,"countryCode":61,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"Hospital De Base de São José do Rio Preto - CIP São José","São José do Rio Preto","15090-000",{"type":63,"coordinates":215},[216,217],-49.37944,-20.81972,{"lat":217,"lon":216},[220,224],{"name":221,"role":49,"phone":222,"phoneExt":51,"email":223},"João Daniel","+55(17)3201-5054","joaodcguedes@gmail.com",{"name":225,"role":45,"phone":51,"phoneExt":51,"email":51},"João Daniel, MD",{"facility":227,"status":93,"city":228,"state":51,"zip":229,"country":60,"countryCode":61,"cosmosGeoPoint":230,"geoPoint":234,"contacts":235},"INCA - Instituto Nacional do Cancer","Rio de Janeiro","20230-130",{"type":63,"coordinates":231},[232,233],-43.18223,-22.90642,{"lat":233,"lon":232},[236,240],{"name":237,"role":49,"phone":238,"phoneExt":51,"email":239},"Adriana Melo","+55(21)3207-2985","andreia.melo@inca.gov.br",{"name":241,"role":45,"phone":51,"phoneExt":51,"email":51},"Andreia Melo, MD",{"facility":243,"status":93,"city":196,"state":51,"zip":244,"country":60,"countryCode":61,"cosmosGeoPoint":245,"geoPoint":249,"contacts":250},"AC Camargo Cancer Center","01509-001",{"type":63,"coordinates":246},[247,248],-46.63611,-23.5475,{"lat":248,"lon":247},[251,255],{"name":252,"role":49,"phone":253,"phoneExt":51,"email":254},"Natasha Carvalho","+55(11)2189-5021","natasha.pandolfi@accamargo.org.br",{"name":256,"role":45,"phone":51,"phoneExt":51,"email":51},"Natasha Carvalho, MD",{"facility":258,"status":56,"city":196,"state":51,"zip":259,"country":60,"countryCode":61,"cosmosGeoPoint":260,"geoPoint":262,"contacts":263},"Hospital Municipal Vila Santa Catarina","04378-500",{"type":63,"coordinates":261},[247,248],{"lat":248,"lon":247},[264,269],{"name":265,"role":49,"phone":266,"phoneExt":267,"email":268},"Ana Lucia Neves","2151-1223","0","ana.neves@einstein.br",{"name":270,"role":45,"phone":51,"phoneExt":51,"email":51},"Henrique A Helber, MD",{"facility":5,"status":56,"city":196,"state":51,"zip":272,"country":60,"countryCode":61,"cosmosGeoPoint":273,"geoPoint":275,"contacts":276},"05652-900",{"type":63,"coordinates":274},[247,248],{"lat":248,"lon":247},[277,279,281],{"name":278,"role":49,"phone":51,"phoneExt":51,"email":51},"Fernando Maluf",{"name":280,"role":49,"phone":51,"phoneExt":51,"email":52},"Diogo Bugano",{"name":278,"role":45,"phone":51,"phoneExt":51,"email":51},{"type":283,"investigatorFullName":51,"investigatorTitle":51,"investigatorAffiliation":51,"oldNameTitle":51,"oldOrganization":51},"SPONSOR",[285,288],{"name":286,"class":287},"Bristol-Myers Squibb","INDUSTRY",{"name":289,"class":287},"Brava","100477066","phase-2-nivolumab-ipilimumab-and-chemoradiation-for-cervical-cancer-100477066",false,"NCT05492123","Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer","Randomized Phase II Study to Evaluate Induction Nivolumab-Ipilimumab, Followed by Nivolumab With Chemoradiotherapy Versus Chemoradiotherapy for Advanced Cervical Cancer","Inclusion Criteria:\n\n* Female participants older than 18 years\n* Documented evidence of cervical adenocarcinoma or squamous carcinoma FIGO Stage IB2-IB3 node positive or Stage IIB-IVA\n* No prior chemotherapy, immune checkpoint inhibitors or radiotherapy for cervical cancer\n* WHO\u002FECOG performance status of 0-1\n* At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 Target Lesion at baseline.\n\nExclusion Criteria:\n\n* Diagnosis of small cell (neuroendocrine) histology cervical cancer\n* Intent to administer a fertility-sparing treatment regimen\n* Undergone a previous hysterectomy\n* Evidence of metastatic disease per RECIST 1.1 including lymph nodes ≥15 mm (short axis) above the L1 cephalad body or outside the planned radiation field.\n* History of allogeneic organ transplantation\n* Active or prior documented autoimmune or inflammatory disorders\n* Uncontrolled intercurrent illness\n* History of another primary malignancy and active primary immunodeficiency\n* Patients with active infection\n\nLaboratory values that fall into:\n\n1. WBC count (WBC) \\\u003C 2000\u002FμL ;\n2. Neutrophil count \\\u003C 1500\u002FμL;\n3. Platelet count \\\u003C 100 x 103\u002FμL;\n4. Hemoglobin level \\\u003C 9.0 g\u002FdL;\n5. Serum creatinine \\> 1.5 x upper limit of normal (ULN) unless creatinine clearance is\n\n   ≥ 40 mL\u002Fmin (measured or calculated using the Cockcroft-Gault formula);\n6. Aspartate aminotransferase (AST)\u002FAlanine aminotransferase (ALT): \\> 3.0 x ULN;\n7. Total bilirubin \\> 1.5 x ULN (except participants with Gilbert Syndrome who must have a total bilirubin level of \\\u003C 3.0 x ULN);\n8. Any positive test result for hepatitis B virus or hepatitis C virus that indicates the presence of the virus, for example, positive Hepatitis B surface antigen (HBsAg, Australia antigen) or Hepatitis C antibodies (anti- HCV) positive (unless the HCV-RNA is negative).\n\n   * Participants with a condition requiring systemic treatment or with corticosteroids (\\>10 mg daily of a prednisone equivalent) or other immunosuppressive drugs within 14 days of initiating study treatment.\n   * Pregnant or breastfeeding woman","FEMALE","18 Years","95 Years",{"count":301,"type":302},112,"ESTIMATED","INTERVENTIONAL",[305],"PHASE2","A total of 112 patients with locally advanced cervical cancer will be randomized 1:1 to standard therapy with cisplatin-based chemoradiation or nivolumab-ipilimumab induction followed by cisplatin-based chemoradiation. The primary outcome will be 3-year disease-free survival.",[308],"Uterine Cervical Neoplasms",[308,310,311,37,312,313,314,15],"Nivolumab","Ipilimumab","Anti-PD1","Anti-PDL1","Anti-CTLA4","2024-01-03",{"date":317,"type":318},"2024-01-05","ACTUAL",{"date":320,"type":318},"2022-08-30",{"date":322,"type":302},"2028-03-31",{"name":5,"class":6},14]